Skinvisible Granted Patent for UVA Absorber, Invisicare

Comments
Print

LAS VEGAS—Skinvisible Inc., a developer of topical and transdermal formulations using its patented Invisicare technology, was granted a new patent from the U.S. Patent and Trademark Office for "Sunscreen Composition With Enhanced UVA Absorber Stability and Methods", Patent Number 8128913. The patent provides protection for its sunscreen formulation in the United States until November 2029.

Skinvisible has developed three sunscreen formulations using avobenzone; SPF 15, 30 and 50. Although avobenzone is recognized as one of the best sun absorber in the United States providing UVA protection, it is known to degrade in sunlight in less than two hours, resulting in less skin protection over time. Skinvisible's new formulation with avobenzone has eight hours of photostability. The essential benefits of Skinvisible's sunscreen formulations are derived from its patented Invisicare polymer delivery system. This patent adds a distinctive new category of Invisicare to Skinvisible's portfolio, one which adds the benefit of photostability to sunscreen formulations and other future developments.

While the SPF of a sunscreen only provides the level of UVB protection, a sunscreen with UVA protection protects the skin from UV rays that penetrate deeper, go through glass and clouds and can cause more severe skin damage, wrinkling and even skin cancer. Skinvisible's sunscreens to meet the new FDA's 2012 guidelines and therefore can be labeled as having "broad spectrum" UV protection.

"With global sales in sun care reaching $1.7 billion in 2010 and North America accounting for 21 percent of that market, the value of this patented asset is tremendous," said Terry Howlett, president and CEO, Skinvisible. "This patent maximizes the earning potential of our sunscreen formulations giving them an increased value when licensed. Skinvisible persists in securing a licensing agreement for its sunscreen formulations with the objective of maximizing revenue generation and continuing our mission of creating value for our company and its shareholders."

Sources:

Comments